Achieve Life Sciences Inc... (ACHV)
3.29
0.14 (4.44%)
At close: Jan 15, 2025, 3:59 PM
3.28
-0.30%
After-hours Jan 15, 2025, 04:00 PM EST
Company Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license agreements with Sopharma AD and University of Bristol.
The company is based in Vancouver, Canada.
Achieve Life Sciences Inc.
| Country | CA |
| IPO Date | Oct 12, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Dr. Richard A. B. Stewart |
Contact Details
Address: 1040 West Georgia Street Vancouver, BC CA | |
| Website | https://www.achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. B. Stewart | Chief Executive Officer & Executive Director |
| Mark K. Oki CPA | Chief Financial Officer |
| Craig Donnelly | Executive Vice President of CMC & Regulatory CMC |
| Dr. Anthony Clarke Ph.D. | Chief Scientific Officer |
| Dr. Cindy Jacobs M.D., Ph.D. | President, Chief Medical Officer & Director |
| Dr. Mark L. Rubinstein | Head of Medical Affairs |
| Jaime Xinos | Chief Commercial Officer |
| Jerry Wan | Principal Accounting Officer |
| Thomas B. King M.B.A. | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 3 | Filing |
| Jan 14, 2025 | 3 | Filing |
| Jan 10, 2025 | S-8 | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 09, 2024 | 4 | Filing |